Raymond James Financial Inc. acquired a new stake in InflaRx (NASDAQ:IFRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 638,092 shares of the company's stock, valued at approximately $1,576,000. Raymond James Financial Inc. owned 1.08% of InflaRx as of its most recent SEC filing.
InflaRx Price Performance
InflaRx stock traded down $0.04 during mid-day trading on Friday, reaching $1.01. The company had a trading volume of 319,785 shares, compared to its average volume of 222,328. The stock's 50-day simple moving average is $1.66 and its 200-day simple moving average is $1.88. InflaRx has a 1 year low of $0.97 and a 1 year high of $2.82. The company has a market capitalization of $67.80 million, a P/E ratio of -0.94 and a beta of 2.21.
InflaRx (NASDAQ:IFRX - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.18. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. On average, equities analysts forecast that InflaRx will post -1.04 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on IFRX. HC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of InflaRx in a report on Friday, March 21st. Guggenheim raised their target price on InflaRx from $7.00 to $10.00 and gave the company a "buy" rating in a report on Wednesday, March 26th.
Get Our Latest Stock Analysis on InflaRx
InflaRx Company Profile
(
Free Report)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
Further Reading
Before you consider InflaRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.
While InflaRx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
